Exemestane 25mg/tab 30 Tabletten by Magnus Pharmaceuticals

Usage

1. Obtain pre-cycle and pre-PCT bloodwork including serum estradiol, total testosterone, and LH/FSH to establish your individual suppression baseline before beginning Exemestane.
2. Begin Exemestane approximately 24–48 hours after the last dose of your mild anabolic compound, once exogenous hormone levels have begun to decline naturally.
3. For mild cycles, split one 25mg tablet to achieve a 12.5 mg unit using a clean tablet cutter — the uniform Magnus tablet matrix supports consistent halving.
4. Take your dose orally with a meal containing dietary fat; Exemestane bioavailability increases by approximately 40% when co-administered with fatty food (per published pharmacokinetic data).
5. Adhere to your selected frequency — daily or every other day — without skipping doses, as consistent enzyme suppression is more important than dose size in a mild-cycle context.
6. Retest serum estradiol and testosterone at the end of your mini-PCT (week 3 or 4) to confirm adequate recovery before discontinuing; adjust to a longer course only if bloodwork indicates persistent suppression.

Warnings

Frequently asked questions

Do you actually need an aromatase inhibitor for PCT after a mild anabolic cycle?

Yes, but at a reduced intensity compared to heavy-cycle recovery. Mild cycles still elevate estrogen relative to the suppressed testosterone baseline during early recovery, making a short AI window beneficial to prevent estrogen-dominant symptoms. Exemestane at 12.5 mg every other day is often sufficient — a far lighter approach than the full-dose AI protocols used after high-dose, long-duration cycles.

How short can a mini-PCT with Exemestane realistically be after a mild cycle?

A mini-PCT using Exemestane can run as briefly as three weeks for mild, short cycles — for example, a sub-12-week low-dose testosterone run. The 24-hour half-life of Exemestane means enzyme suppression persists between doses, so even an every-other-day schedule maintains meaningful aromatase inhibition across a compressed recovery window without requiring a longer commitment.

Is a SERM still necessary alongside Exemestane in a mild-cycle mini-PCT?

In truly mild suppression scenarios, many practitioners run Exemestane without a SERM, relying on the AI to manage estrogen while endogenous testosterone recovers naturally. However, if cycle length exceeded ten weeks or baseline bloodwork shows deeper HPT suppression than expected, adding a low-dose SERM alongside Exemestane provides a more robust two-pronged recovery approach.

Can the Magnus Pharmaceuticals 25mg Exemestane tablet be split to achieve 12.5 mg doses?

Yes. The compressed tablet matrix of Magnus Exemestane supports splitting into two equal halves for 12.5 mg units — the dose most commonly used in mild-cycle mini-PCT schedules. Uniform API distribution, verified during compression under GMP conditions, ensures each half delivers a consistent dose rather than an unpredictable fragment.

How many tablets from the 30-tablet pack does a typical mild-cycle mini-PCT consume?

A four-week mini-PCT at 12.5 mg daily uses 28 tablets, fitting neatly within the 30-tablet pack with two tablets to spare. Running at 12.5 mg every other day across four weeks uses only 14–15 tablets — meaning one pack covers two full mild-cycle recovery courses at that frequency, offering practical economy for repeat users. (2) angle_used

Manufacturer

The Exemestane 25mg/tab formulation within Magnus Pharmaceuticals' oral product line reflects a release-process architecture in which batch approval is conditional on two independent analytical outputs rather than a single pass/fail inspection point. First, incoming Exemestane API is subjected to LAL endotoxin screening before it enters any granulation stage — a raw-material gate that prevents contaminated starting substance from reaching compression. Second, finished tablets from each production lot undergo HPLC potency analysis, generating a quantitative per-tablet API figure that is retained in the batch record as instrument-derived documentation. The result is a Pharma Grade Exemestane tablet whose potency claim is traceable to a specific analytical method and lot number, not to a general manufacturing statement. This two-stage documentation approach governs the oral PCT sub-line across the Magnus Pharmaceuticals portfolio, applied independently to each active ingredient rather than as a batch-level formality.